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To clarify the physiological role of Na+-D-glucose cotransporter
SGLT1 in small intestine and kidney, Sglt12/2 mice were gener-
ated and characterized phenotypically. After gavage of D-glucose,
small intestinal glucose absorption across the brush-border mem-
brane (BBM) via SGLT1 and GLUT2were analyzed. Glucose-induced
secretion of insulinotropic hormone (GIP) and glucagon-like pep-
tide 1 (GLP-1) in wild-type and Sglt12/2 mice were compared.
The impact of SGLT1 on renal glucose handling was investigated
by micropuncture studies. It was observed that Sglt12/2 mice de-
veloped a glucose-galactose malabsorption syndrome but thrive
normally when fed a glucose-galactose–free diet. In wild-type mice,
passage of D-glucose across the intestinal BBM was predominantly
mediated by SGLT1, independent the glucose load. High glucose
concentrations increased the amounts of SGLT1 and GLUT2 in
the BBM, and SGLT1 was required for upregulation of GLUT2.
SGLT1 was located in luminal membranes of cells immunopos-
itive for GIP and GLP-1, and Sglt12/2 mice exhibited reduced
glucose-triggered GIP and GLP-1 levels. In the kidney, SGLT1 re-
absorbed ;3% of the filtered glucose under normoglycemic con-
ditions. The data indicate that SGLT1 is 1) pivotal for intestinal
mass absorption of D-glucose, 2) triggers the glucose-induced
secretion of GIP and GLP-1, and 3) triggers the upregulation of
GLUT2. Diabetes 61:187–196, 2012
Obesity, type 2 diabetes, and the metabolic syn-drome are some of the major medical andeconomical challenges of modern societies.Dysregulation of carbohydrate management,
increased consumption of carbohydrates and fat, and re-
duced insulin receptor sensitivity contribute to the meta-
bolic derangements. Drugs that reduce small intestinal
uptake of D-glucose and/or reabsorption of D-glucose from
the renal filtrate or that modulate secretion of insulino-
tropic enterohormones can provide new therapeutic strat-
egies (1,2). To further explore these options a better
understanding of the underlying molecular mechanisms
is required.
The primary transporters that mediate transcellular
movements of D-glucose in small intestine have been iden-
tified and include the Na+-D-glucose cotransporter SGLT1
and GLUT2 (3,4). It is generally accepted that SGLT1 medi-
ates uptake of low concentrations of D-glucose across the
brush-border membrane (BBM) of the small intestine and
that D-glucose leaves enterocytes across the basolateral
membrane (BLM) via GLUT2 (3). However, their relative
contributions to D-glucose absorption after a carbohydrate-
rich meal remain controversial (5–7). Kellet and coworkers
suggested that under these conditions GLUT2 is incor-
porated into the BBM allowing mass absorption of D-glucose
via GLUT2 (5,6,8). However, the observation that small in-
testinal mass absorption of D-glucose in mice was not
significantly changed when GLUT2 was removed (9) con-
tradicts this hypothesis.
Among other dietary stimulants, D-glucose can trigger
the intestinal secretion of glucose-dependent insulino-
tropic peptide (GIP) by K-cells as well as the secretion
of glucagon-like peptide 1 (GLP-1) by L-cells (10–12).
Potential glucose sensing systems expressed in these
enteroendocrine cells include sweet taste receptors and
glucose transporters like SGLT1, but their roles in glucose-
induced secretion of GLP-1 and GIP have not been fully
established (7,13–16).
There is agreement that the bulk of D-glucose filtered in
the glomeruli of the kidney is reabsorbed in the S1 and S2
segments of proximal tubules via SGLT2 in the BBM and
GLUT2 in the BLM (17), and it is generally assumed that
the remaining glucose is reabsorbed in the S2 and S3 seg-
ments via SGLT1 in BBM and GLUT1 in the BLM. However,
the physiological significance and quantitative contribution
of SGLT1 for renal reabsorption of D-glucose has not been
directly determined (17).
In the present work we generated and characterized the
phenotype of an Sglt12/2mouse model to gain new insights.
We report that these mice show symptoms of the glucose-
galactose malabsorption (GGM) syndrome (OMIM 182380)
that appears to be cured by a diet low in glucose and ga-
lactose (18,19). The experiments identify SGLT1 as the
primary pathway for the transport of D-glucose across
the BBM during D-glucose mass absorption and show that
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SGLT1 is essential for the glucose-induced release of GIP
and GLP-1 into the peripheral circulation. Finally, we es-
tablish a small but significant contribution of SGLT1 to renal
D-glucose reabsorption under normoglycemic conditions.
RESEARCH DESIGN AND METHODS
Animal handling. Mice were handled in compliance with Institutional
guidelines and German, U.K., and U.S. laws. Comparison between Sglt12 /2
and wild-type mice was performed between the 8th and 12th generation of
backcrossing of Sglt12/2 (129/OLA/C57BL/6 background) with wild-type (C57BL/
6 background). Animals were kept in a temperature-controlled environment with
a 12-h–light/12-h–dark cycle.
Diets. Standard maintenance chow (Ssniff V1534–000 R/M-H, 10 mm) was
obtained from Spezialdiäten GmbH, Soest, Germany. It contained 12.8 MJ kg21
metabolizable energy and was composed of 36.4% starch, 19% protein, 4.9%
fiber, 4.7% mono- and disaccharides, and 3.3% fat, minerals, and vitamins.
The glucose-galactose–free diet was prepared by Altromin Spezialfutter GmbH
(Lage, Germany) and contained 13.2 MJ kg21 metabolizable energy. It was com-
posed of 33.8% protein, 30.7% fiber, and 20.5% fat, minerals, and vitamins.
Antibodies. The antibodies used are described in Table 1.
Immunohistochemistry. Immunofluorescence histochemistry was performed
with cryo-sections of p-formaldehyde–fixed tissue as described (22). For
double staining sections were first incubated with GIP-Ab or GLP-1-Ab and
respective secondary antibody and washed. Thereafter sections were in-
cubated overnight at 4°C with SGLT1-Ab, rinsed with PBS, incubated with
GAR-AF555 for 60 min at room temperature, and washed. Laser scanning
fluorescence microscopy was performed with a confocal laser-scanning im-
aging system, LSM-510 using the argon laser for green fluorochromes (lex =
488 nm, LP505 nm), and the helium-neon laser for red fluorochromes (lex =
543 nm, BP560–615 nm) (Zeiss, Jena, Germany). The Zeiss LSM-510 software
2.5 SP2 stack, multi track, 8 bit scan mode was used.
Gavage with glucose and oil. After a 16- to 18-h fasting period mice were
gavaged with a 10% D-glucose solution (2 mg/g body wt) in PBS, a 40% D-glucose
solution (6 mg/g body wt) in PBS, or with olive oil (10 mL/g body wt). Control
animals were gavaged with PBS.
Measurements of glucose, insulin, and enterohormones in the plasma.
For determination of D-glucose and insulin blood was collected from the tail.
Concentrations of D-glucose were determined with an Ascensia CONTOUR
Meter using Ascensia MICROFIL Test Strips (Bayer Vial GmbH, Leverkusen).
Insulin levels were measured with the Insulin (Mouse) Ultrasensitive EIA from
ALPCO Diagnostics (Salem, NH). For determination of enterohormones, mice
were anesthetized with isoflurane and blood was collected after heart tap. For
GLP-1 determination blood was immediately mixed with a dipeptidyl pepti-
dase (DPP)-IV inhibitor yielding a final concentration of 100 mmol/L (Millipore
Corporation, Billerica, MA). Active GLP-1 was determined by an ELISA kit
supplied by Millipore Corporation (GLP-1(7–36) active, kit EGLP-35 K) (Fig.
5C). Total GLP-1 was determined by an ELISA kit provided by MesoScale
Discovery (Gaithersburg, MD; kit K150JVC-4; Fig. 5D and Supplementary Fig.
5B). GIP was determined by an ELISA kit obtained from Millipore Corporation
that is specific for both active GIP (1–42) and inactivated GIP (3–42) of rat and
mouse (kit EZRMGIP-55 K).
Preparation of BBM vesicles from small intestine.Mice were killed 30 min
after gavage. BBM vesicles (BBMVs) were isolated by magnesium precipitation
followed by differential centrifugation. Small intestines of three mice were
homogenized in 35mL of homogenization buffer (100mmol/Lmannitol, 2mmol/L
HEPES/Tris [pH 7.1]). MgCl2 solution (1 mol/L) was added to a concentration of
10 mmol/L, and the suspension was kept on ice for 20 min. After 15 min cen-
trifugation at 3,000 g, the pellet containing nuclei and mitochondria was dis-
carded. The supernatant was centrifuged for 30 min at 27,000 g, and the
resulting pellet was suspended in 35 mL vesicle buffer (100 mmol/L mannitol,
20 mmol/L HEPES/Tris [pH 7.4]). After 30 min centrifugation at 27,000 g, the
pellet was suspended in 300 mL vesicle buffer. The BBMVs were snap-frozen in
liquid nitrogen and stored at 270°C until use.
Glucose uptake into BBMVs. BBMVs were thawed in a water bath, and
uptake of radiolabeled substrates was determined at 22°C using the rapid fil-
tration technique (23). To measure sodium-dependent and phlorizin-inhibitable
uptake of a-methyl-D-glucoside (AMG), vesicles were incubated with vesicle
buffer containing 0.1 mmol/L [14C]AMG plus either 100 mmol/L NaSCN or 100
mmol/L NaSCN plus 0.2 mmol/L phlorizin or 100 mmol/L KSCN. Uptake was
stopped with ice-cold vesicle buffer containing 100 mmol/L NaSCN plus 0.2
mmol/L phlorizin (stop solution), and vesicles were washed on nitrocellulose
filters with stop solution. The radioactivity on the filters was measured and
phlorizin-inhibitable or sodium-dependent AMG uptake was calculated.
To measure GLUT2-mediated D-glucose uptake, which is inhibited by glucos-
amine (24), BBMVs were incubated for 1 min at 22°C with 20 mmol/L HEPES/
Tris [pH 7.4] containing 100 mmol/L [3H]-D-glucose plus 100 mmol/L mannitol
or plus 100 mmol/L D-glucosamine. Uptake was stopped with ice-cold 20
mmol/L HEPES/Tris [pH 7.4] containing 100 mmol/L mannitol plus 100 mmol/L
D-glucosamine, and vesicles were washed on nitrocellulose filters.
Glucose uptake into everted rings. Everted rings of duodenum and jejunum
were incubated for 2 min in Krebs-Ringer buffer containing 7 mmol/L [14C]AMG
without and with 0.2 mmol/L phlorizin. Uptake was stopped with ice-cold
Ringer buffer containing 0.2 mmol/L phlorizin. The length of individual seg-
ments was measured under a microscope, the segments were solubilized, and
radioactivity was analyzed.
Glucose uptake by SGLT1 expressed in oocytes. SGLT1 was expressed in
oocytes of Xenopus laevis, and measurements of AMG uptake were performed
as described (25). The cDNA of mouse Sglt1 (accession number BC003845)
was cloned into the vector pRSSP, and m7G(59)G-capped cRNA was prepared.
Oocytes were injected with 5 ng of mouse Sglt1 cRNA and incubated 2 days
for expression. For transport measurements the oocytes were incubated for 20
min at room temperature with [14C]AMG or [3H]D-glucose in the absence and
presence of 100 mmol/L phlorizin, and phlorizin-inhibited uptake was analyzed.
Renal glucose reabsorption. Glomerular filtration rate (GFR) and renal




Name Antigen Host Source (Cat. No.) Properties (use)
SGLT1-Ab1 mouse SGLT1, aa 586 to 601
(KDTIEIDTEAPQKKKKG)
Rabbit raised for this study see article (pA, WB, IH)
SGLT2-Ab1 rat SGLT1, aa 592–609
(AMGIEEVQSPAPGLLRQC)
Rabbit raised previously (20) cross-reacts with mouse
SGLT2 (pA, WB, IH)
GLUT2-Ab peptide of human GLUT2
(pep C-19, from COOH terminus)
Goat Santa Cruz Biotechnology
(sc-7580)
cross-reacts with mouse GLUT2
(21) (pA, WB, IH)
GIP-Ab human GIP (pep Y-20, from
internal region)
Goat Santa Cruz Biotechnology
(sc-23554)
cross-reacts with mouse GIP
(pA for IH)
GLP-1-Ab human GLP-1 (pep C-17, from
COOH terminus)
Goat Santa Cruz Biotechnology
(sc-7782)
cross-reacts with mouse GLP-1
(pA, IH)
GAR-AF555 rabbit IgG Goat Invitrogen GmbH (A21428) Alexa Fluor 555-labeled (sA, IH)
CAG-488F goat IgG Chicken Invitrogen GmbH (A21467) Alexa Fluor 488-labeled (sA, IH)
DAR-HRP rabbit IgG Donkey Dianova (711–035–152) Horseradish peroxidase-labeled
(sA, WB)
DAG-HRP goat IgG Donkey Dianova (705–035–147) Horseradish peroxidase-labeled
(sA for WB)
aa, Amino acids; WB, Western blot; IH, immunohistochemistry; pA, primary antibody; pep, peptide; sA, secondary antibody. 1Affinity-purified
via the respective antigenic peptide as described (20).
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RESULTS
Removal of SGLT1 leads to GGM syndrome. The
strategy to generate mice lacking part of the Sglt1 promotor
and the first exon of Sglt1 is outlined in Supplementary
Fig. 1A. Sglt1+/2 mice and Sglt12/2 mice were identified
by Southern blots and PCR (Supplementary Fig. 1B and C).
To verify effects on glucose transport, we expressed
murine Sglt1 or murine Sglt1 mutant without exon 1 in Xen-
opus laevis oocytes and measured phlorizin (100 mmol/L)-
inhibitable uptake of 50 mmol/L AMG, a SGLT-specific
substrate that is not transported by GLUT transporters.
Whereas a high transport activity was observed after ex-
pression of SGLT1 wild type, no significant AMG uptake
was observed with the SGLT1 mutant (Supplementary
Fig. 2). Breeding of Sglt1 heterozygote mice demon-
strated Mendelian type inheritance (from 531 outcomes
51% were heterozygotes, 27% wild type, and 22% Sglt12/2),
indicating embryonic survival of Sglt12/2 mice. Whereas
preweaning Sglt12/2 mice appeared to be healthy, Sglt12/2
mice died within 2 days after weaning when they received
standard diet. In contrast, weaned Sglt12/2 mice survived
well and were fertile when they were fed a diet that did
not contain free monosaccharides and disaccharides (Fig.
1A). To determine whether the inactivation of Sglt1 in mice
induced a GGM syndrome as in humans (19), two-month-
old mice fed with glucose-galactose–free diet were transi-
tioned to standard diet (Fig. 1B). Whereas wild-type mice
did not show a significant change in weight, the Sglt12/2
mice appeared unwell after 2 days, became weaker, lost
body weight, and died within 7 to 12 days after the dietary
change (Fig. 1B). Laparatomy 2 days after reapplication of
standard diet revealed distended small and large intestines
in the Sglt12/2 mice (Fig. 1C). Absence of Sglt1 mRNA and
SGLT1 protein in the small intestine of Sglt12/2 mice was
verified by Northern blotting, Western blotting, and immuno-
histochemistry (Fig. 1D–F).
To determine the contribution of SGLT1 to Na+-D glu-
cose cotransport across BBM of small intestine we com-
pared AMG uptake across the BBM of wild-type versus
Sglt12/2 mice. Comparison was performed in mice fed
a glucose-galactose–free diet. Three methods were used:
measurement of phlorizin-inhibitable AMG uptake into
everted rings of small intestine (Fig. 1G), measurement of
glucose-induced short circuit currents across small in-
testinal mucosa (Fig. 1H), and measurement of phlorizin-
inhibitable AMG uptake into isolated BBMVs (Fig. 2C). The
data show that absence of SGLT1 abolishes Na+-D-glucose
cotransport across the small intestinal BBM. Mice express
SGLT1 homologs SGLT3a and SGLT3b (30). Confirming
recently reported data (30), we observed phlorizin-inhibitable
uptake of AMG after expression of SGLT3b in oocytes of
Xenopus laevis. By comparison, phlorizin-inhibitable AMG
uptake could not be detected after expression of SGLT3a
(Supplementary Fig. 3A). Using immunohistochemistry
we observed immunoreactivity of an antibody raised
against SGLT3b at the BBM of small intestinal enterocytes
(Supplementary Fig. 3B). The functional data in BBMs,
however, indicate that SGLT3b activity cannot substitute for
SGLT1.
Small intestinal mass absorption of D-glucose across
the BBM is mainly mediated by SGLT1. Kellet and
coworkers raised the hypothesis that at high luminal glu-
cose concentrations GLUT2 is incorporated into the BBM
and is the dominant pathway for D-glucose translocation
across the BBM under these conditions (5,6,8). These
authors postulated that the incorporation of GLUT2 into
the BBM is triggered by SGLT1 activity leading to activation
of the Ca2+ channel Cav1.3 (5,8). However, in a more recent
review it was proposed that Cav1.3 is activated by sweet
taste receptors and endocrine and paracrine hormones in-
cluding insulin (6).
We compared the increase of plasma D-glucose con-
centrations after gavage of a solution containing D-glucose
(2 mg/g body wt) in wild-type versus Sglt12/2 mice (Fig.
2A). In wild-type mice the increase of D-glucose concen-
trations in plasma was significantly higher than in Sglt12/2
mice (3.3-fold vs. 1.8-fold after 13 min). The increase of
plasma D-glucose after glucose gavage in Sglt12/2 mice
(1.8 6 0.2-fold) was similar in magnitude to the increase
observed in Sglt12/2 mice (1.8 6 0.1-fold) and wild-type
mice (1.7 6 0.1-fold) after gavage of solvent control (Fig.
2A) and may reflect stress (adrenalin)-induced release of
D-glucose from the liver. These data provide evidence that
SGLT1 is required for small intestinal mass absorption of
D-glucose.
To determine whether D-glucose transport across the
BBM after a glucose bolus is mediated by SGLT1 or GLUT2
we performed studies with BBMVs from wild-type and
Sglt12/2 mice. About 10-fold higher Km values were ob-
tained for SGLT1-mediated uptake of D-glucose/AMG ac-
ross small intestinal BBMs of wild-type mice compared
with values obtained from Xenopus oocytes expressing
mouse SGLT1 (Fig. 3). BBMVs were prepared from mice
gavaged with PBS or PBS containing D-glucose (6 mg/g
body wt) and killed 30 min later. Whereas in BBMVs of
wild-type mice, which received the glucose bolus, the Km
value of sodium-dependent AMG uptake was modestly
(25%) reduced compared with wild-type mice receiving
only PBS (Fig. 2B), the Vmax value of AMG uptake was 4.4-
fold increased (Fig. 2C). The corresponding amount of
SGLT1 protein in BBMVs estimated from Western blots
was increased 2.4-fold (Fig. 2D). In BBMVs of Sglt12/2
mice no uptake of the SGLT specific substrate AMG was
detectable without and with D-glucose gavage (Fig. 2C).
The data indicate upregulation of SGLT1 expression in the
BBM after gavage with D-glucose in mice.
Maximal transport activity (Vmax) of GLUT2 across the
BBM was determined by measuring the uptake of 100
mmol/L D-glucose (partially [3H]-labeled) that could be
blocked by the GLUT2 specific inhibitor glucosamine (100
mmol/L) (24). In oocytes expressing mouse SGLT1 we
verified that glucosamine does not inhibit SGLT1 (Sup-
plementary Fig. 4). Vmax of GLUT2-mediated D-glucose
uptake into BBMVs in wild-type mice without glucose ga-
vage was similar to Sglt12/2 mice without or with glucose
gavage (43–70 pmol 3 mg21 3 s21; Fig. 2E). Gavage of
D-glucose increased Vmax of GLUT2-mediated D-glucose
uptake into BBMVs of wild-type mice 2.7-fold (168 6 31
pmol3mg213 s21). Western blots using antibodies against
GLUT2 from human (GLUT-Ab) that cross-react with
mouse GLUT2 (21) showed a similar magnitude in the
increase of GLUT2 protein expression in BBMVs of wild-
type mice after the D-glucose bolus (Fig. 2F). The increase
in both the GLUT2 protein expression and the GLUT2-
mediated D-glucose uptake in response to the glucose
bolus were blunted in Sglt12/2 mice. These findings are
consistent with a role of SGLT1 in the upregulation of
GLUT2 activity in the BBM by high glucose concentration.
Without D-glucose bolus the Vmax of AMG uptake via
SGLT1 was 5.5 times higher than maximal D-glucose up-
take via GLUT2, and after glucose gavage the Vmax of AMG
V. GORBOULEV AND ASSOCIATES
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uptake via SGLT1 was 8.7 times higher compared with
D-glucose uptake via GLUT2 (compare Fig. 2C and E).
This indicates that D-glucose uptake via the luminal
membrane of small intestinal enterocytes is predomi-
nantly (.80%) mediated via SGLT1.
SGLT1 is expressed in L-cells and K-cells. We inves-
tigated the expression of SGLT1 in enteroendocrine L-cells
and K-cells, which are known to secrete GLP-1 and GIP,
respectively (Fig. 4). Immunohistochemistry was performed
using double staining with specific primary antibodies raised
FIG. 1. Deletion of Sglt1 in small intestine leads to GGM syndrome that can be prevented by a glucose-galactose–reduced diet. A: Body weight de-
velopment after weaning. Sglt1+/2 mice receiving standard diet (s.d.) were bred. Newborn mice were genotyped 3 weeks after birth. After weaning,
Sglt1+/+ and Sglt12/2 mice were kept on standard diet or glucose/galactose-reduced diet (r.d.). Mean values 6 SE of 8 animals are shown. B: Body
weight development of 2-month-old mice that have been kept on glucose-galactose–reduced diet and were then switched to standard diet. Mean
values 6 SE are shown; n = 5 wild-type and 5 Sglt12/2 mice (initial number of mice). †Death of one Sglt12/2 mouse; ††Death of two SGLT12/2 mice.
C: Appearance of abdominal contents of 2-month-old mice kept on glucose-galactose–reduced diet after weaning that were fed 2 days with standard
diet. D: Northern blots with mRNAs isolated from small intestines of 2-month-old mice hybridized with cDNA fragments of Sglt1 or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). A 176 bp Sglt1 fragment comprising nucleotides 1727–1902 (accession number AF163846) and a 1.1 kb fragment
of human GAPDH (Clontech, Heidelberg, Germany) was used.E: Western blots of small intestinal BBMs of 2-month-old mice, which were performed as
described (28), were stained with antibody against SGLT1 (SGLT1-Ab, diluted 1:2,000). F: Immunohistochemistry of small intestine with SGLT1-Ab
(dilution of SGLT1-Ab, 1:1,000; scale bar, 20mm). G: Phlorizin-inhibitable uptake of 7 mmol/L AMG into enterocytes of everted rings of small intestine.
Because phlorizin-inhibitable AMG uptake in duodenum and jejunum was not significantly different the measurements from both regions were
combined. Mean values of phlorizin-inhibitable AMG uptake6 SE from four independent experiments are shown.H: D-glucose induced transepithelial
short-circuit currents (Isc). Small intestinal mucosa mounted into Ussing chambers was superfused at 37°C in the presence of 20 mmol/L mannitol or
20 mmol/L D-glucose, and electrogenic glucose uptake was measured as described (29). Mean values 6 SE of five experiments. *P < 0.05, **P < 0.01,
***P < 0.001 determined by Student t tests. (A high-quality digital representation of this figure is available in the online issue.)
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in rabbit or goat and fluorophore-labeled secondary anti-
bodies raised in chicken. Fluorescence was visualized by
laser scanning microscopy using an optical section thick-
ness of 0.1 mm. Coexpression of SGLT1 with GLP-1 and
GIP was observed in individual cells of jejunal crypts.
SGLT1-Ab immunoreactivity was observed at the BBM of
enteroendocrine cells, whereas immunoreactivities for
antibodies against GIP or GLP-1 were predominantly ob-
served in intracellular compartments (Fig. 4).
SGLT1 is required for elevated systemic blood
concentrations of GIP and GLP-1 after gavage with
D-glucose. Oral application of D-glucose stimulates the
pancreatic secretion of insulin more than intravenous
application. In humans, this surplus of insulin secretion
is a result of the combined effects of GIP and GLP-1
(12,31). After exposure of the small intestine to high
glucose the concentrations of these enterohormones
increase in systemic blood.
Thirteen minutes after glucose gavage (2 mg/g body wt),
plasma insulin was approximately two times higher in
wild-type mice compared with Sglt12/2 mice (Fig. 5A). At
the same time, GIP was increased ;10-fold in the systemic
blood of wild-type mice but was not changed in Sglt12/2
mice (Fig. 5B). By comparison 13 min after gavage with
olive oil (10 mL/g body wt), GIP increased four- to fivefold
in the systemic blood of both wild-type and Sglt12/2 mice.
Thirteen minutes after glucose gavage the active GLP-1
concentration in systemic blood was not increased in wild-
type or Sglt12/2 mice, whereas application of oil induced
a SGLT1-independent twofold increase in active GLP-1
(Fig. 5C). Because the concentration of active GLP-1 in
systemic blood may be reduced by degradation we also
measured total GLP-1 in the systemic blood 5 min after
gavage of a greater D-glucose load (6 mg/g body wt; Fig. 5D).
Under these conditions a significant glucose-dependent
increase of GLP-1 concentration was observed in wild-type
mice but not in Sglt12/2mice. Measuring glucose-dependent
stimulation of GIP and GLP-1 secretion from primary in-
testinal cultures prepared from Sglt1+/2 and Sglt2/2 mice,
we confirmed that SGLT1 is required for glucose-dependent
stimulation of these enterohormones (Supplementary
Fig. 5).
SGLT1 in renal proximal tubules is required for
complete reabsorption of filtered D-glucose. In kid-
ney the low affinity Na+-D-glucose cotransporter SGLT2 is
located in BBMs of S1 segments of proximal tubules,
whereas the high affinity Na+-D-glucose cotransporter
SGLT1 is located in BBMs of the S2 and S3 segments
(20,22). We confirmed that no expression of SGLT1 was
observed in kidneys of Sglt12/2mice (Supplementary Figs.
FIG. 2. Upregulation of small intestinal D-glucose absorption after ap-
plication of a D-glucose bolus to the stomach. A: D-glucose concen-
trations in the plasma after gavage with D-glucose (2 mg/g body wt;
Sglt1+/+,●, Sglt12/2,○) or buffer (Sglt1+/+,■; Sglt12/2,□). ***P< 0.001,
Sglt1+/+ mice after glucose gavage vs. Sglt12/2 mice after glucose
gavage; cccP < 0.001 differences to the D-glucose concentration in
Sglt12/2 mice before glucose gavage. B-F: Properties of small intestine
BBMVs of control Sglt1+/+ and Sglt12/2 mice (2bolus) and of Sglt1+/+
and Sglt12/2 mice that had received a D-glucose bolus (6 mg/g body wt)
30 min earlier (+bolus). B: Km values for AMG of Na
+-dependent uptake
of [14C]AMG into BBMVs. Uptake rates were measured after incubation
for 5 s in the presence of an inwardly directed gradient of 100 mmol/L
NaSCN or 100 mmol/L KSCN, and the differences were calculated. C:
Phlorizin-inhibitable uptake of AMG into BBMVs. Uptake of 0.1 mmol/L
[14C]AMG was measured after incubation for 2 s in the absence and
presence of 200 mmol/L phlorizin, and the differences were calculated.
Vmax values were calculated according to the Michaelis Menten equa-
tion using the Km values determined in B. D: SGLT1 protein expressed
in BBMVs. Western blots of BBMVs (26) were stained with SGLT1-Ab
(diluted 1:2,000), and the staining was quantified by densitometry. E:
Glucosamine-inhibitable uptake of D-glucose into BBMVs. Uptake rates
of 100 mmol/L [3H]D-glucose were measured in the absence and pres-
ence of 100 mmol/L D-glucosamine, and the differences were calculated.
Because the Michaelis Menten constant (Km) value of mouse GLUT2 for
D-glucose is ;17 mmol/L (4), the uptake rates of 100 mmol/L D-glucose
represent Vmax values. E: GLUT2 protein expression in BBMVs. Western
blots of BBMVs (27) were stained with antibody against human GLUT2
(diluted 1:500) cross-reacting with mouse GLUT2. Staining was quanti-
fied by densitometry. Means 6 SE are presented. The number of in-
dependent experiments is indicated in parentheses. Significances of
differences are calculated by ANOVA with post hoc Tukey comparison. *P
< 0.05; **P < 0.01; ***P < 0.001; rel., relative.
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6A and 7A) and determined at mRNA and protein levels
that the expression of SGLT2 was not changed after re-
moval of SGLT1 (Supplementary Figs. 6B and 7B and C).
In wild-type and Sglt12/2 mice similar mRNA and protein
concentrations of the passive glucose transporters GLUT1,
GLUT2, and GLUT5 were determined (Supplementary Fig.
7B and C).
Spontaneous urine collections in awake male mice re-
vealed that urinary glucose concentrations were signifi-
cantly increased in Sglt12/2 compared with wild-type mice,
whereas blood glucose levels were not different (Fig. 6A).
Fractional glucose reabsorption was 100% in male wild-
type and 97% in male Sglt12/2 mice (Fig. 6B). In male
mice, GFR measured in awake and anesthetized animals,
blood pressure, heart rate, plasma urea concentrations,
food intake and fluid intake, and renal excretion of fluid,
Na+, and Cl2 were not changed after removal of SGLT1.
Details and differences in food intake and fluid intake
between males and females are described in the Supple-
mentary Data.
Quantitative free-flow collections of tubular fluid were
performed from the last surface loop of proximal convo-
luted tubules. Mean values for single nephron GFR and the
amount of glucose filtered per nephron were not different
between male Sglt12/2 and wild-type mice (Fig. 7A and B).
However, the concentration and delivery of glucose were
increased in Sglt12/2 versus wild-type mice, whereas frac-
tional glucose reabsorption was reduced (Fig. 7C and D).
In contrast with fractional reabsorption of glucose, frac-
tional reabsorption of fluid and chloride was not signifi-
cantly different between male Sglt12/2 and wild-type mice
(fluid: 0.48 6 0.02 vs. 0.45 6 0.03; chloride: 0.47 6 0.03 vs.
0.45 6 0.03; n = 17–25 nephrons in each group, not sig-
nificant).
DISCUSSION
In the current study the role of SGLT1 for small intestinal
glucose absorption and incretin secretion was investigated
comparing nondiabetic mice without and with expression
of SGLT1. Evidence is presented that SGLT1 mediates the
majority of D-glucose transport across the BBM of enter-
ocytes independent of the glucose load. SGLT3b, a second
functional Na+-D-glucose cotransporter in the BBM of
FIG. 3. The substrate dependence of SGLT1-mediated glucose uptake
expressed in oocytes is different from the substrate dependence of
SGLT1-mediated glucose uptake across small intestinal BBM. A and B:
Transport measurements in oocytes. Oocytes were injected with 5 ng
of mouse Sglt1 cRNA and incubated 2 days for expression. Uptake of
different concentrations of [14C]AMG (A) or [3H]D-glucose (B) was
measured in the absence and presence of 100 mmol/L phlorizin. Phlorizin-
inhibitable uptake rates of individual experiments were normalized to the
uptake rates measured at 2 mmol/L AMG or D-glucose. Mean values + SE
of 25–30 oocytes from 3 independent experiments are shown. Similar
apparent Km values of 0.17 6 0.05 mmol/L and 0.13 6 0.01 mmol/L were
obtained for AMG and D-glucose, respectively. The Vmax values of
SGLT1-mediated uptake of AMG and D-glucose were similar. In oocytes
of the same batch, which were injected with 5 ng of Sglt1 cRNA per
oocyte and incubated for 2 days, Vmax values (measured at mono-
saccharide concentrations of 2 mmol/L without and with 100 mmol/L
phlorizin) of 5.0 6 0.6 (AMG) and 4.8 6 0.6 (D-glucose) pmol 3
oocyte21 3 min21 were obtained (n = 25 each, not significant).
C: Transport measurements in BBMVs. Wild-type mice fed with standard
diet were starved for 18 h and killed at 3–4 P.M. BBMVs were prepared.
BBMVs were incubated for 2 s at 37°C with different concentrations
of [14C]AMG in the presence of an inwardly directed gradient of 100 mmol/L
NaSCN or 100 mmol/L KSCN. The sodium-dependent uptake rates of
individual experiments were normalized to the values obtained at
10 mmol/L AMG. Mean values 6 SE of 12 measurements from three
independent experiments are shown. A Km value of 1.20 6 0.04 mmol/L
(n = 5) was determined. D: Glucose-induced short circuit currents
across small intestinal mucosa. Wild-type mice fed with standard diet
were starved for 18 h and killed at 4 P.M. The jejunal small intestinal
wall was then mounted to an Ussing chamber. The mucosal side was
superfused with different concentrations of D-glucose, and D-glucose–
induced short circuit currents (Isc) mediated by Na
+ -D-glucose cotransport
was measured. Mean values 6 SE of 7 experiments are shown. The
Michaelis Menten equation was fitted to the data. A Km value of 1.9 6
0.6 mmol/L was determined.
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mice, does not contribute significantly. After high glucose
load some GLUT2 is incorporated into the BBM, but this
has minor impact on small intestinal glucose absorption. It
is noteworthy that this translocation of GLUT2 was not
observed in Sglt12/2 mice, indicating that SGLT1 rather
than sweet taste receptors is pivotal in this upregulation
(5,6,8). Without and with D-glucose load the capacity of
SGLT1 versus GLUT2 for D-glucose transport across the
BBMs was 5.5 and 8.7 times higher, respectively. In re-
sponse to continuous feeding of sugar-rich diets and dur-
ing diabetes, however, the contribution of GLUT2 to small
intestinal glucose absorption may become more relevant.
Under these conditions the expression of SGLT1 and
GLUT2 is increased, and an increase of GLUT2 in the
BBM was observed after gavage with glucose or fructose
(32–35).
Removal of SGLT1 in mice resulted in GGM syn-
drome (OMIM 182380) that could be cured by a glucose-
galactose–reduced diet as has been observed in patients
FIG. 4. Expression of SGLT1 in enteroendocrine cells. Sections from
jejunum of mice were first incubated with antibodies against GIP or
GLP-1 raised in goat and then with SGLT1-Ab raised in rabbit (GIP-Ab
and GLP-1 were diluted 1:100, and SGLT1-Ab diluted 1:1,000). Staining
was performed with fluorescent-labeled secondary antibodies (diluted
1:800) against goat IgG (GIP or GLP-1, green) and rabbit IgG (SGLT1,
red). A and B: K-cell in crypts. C: L-cell in a crypt. Scale bar, 5 mm.
(A high-quality digital representation of this figure is available in the
online issue.)
FIG. 5. Secretion of insulin, GIP, and GLP-1 after gavage with D-glucose
in Sglt12/2 mice versus Sglt+/+ mice. A: Effect of D-glucose gavage (2
mg/g body wt) on systemic plasma insulin concentrations. B: Con-
centrations of GIP in systemic blood plasma before and 13 min after
gavage with D-glucose (G bolus; 2 mg/g body wt) or 13 min after gavage
with oil (10 mL/g body wt). C: Concentrations of active GLP-1 in
systemic blood plasma before and 13 min after gavage with D-glucose
(2 mg/g body wt) or oil. D: Concentration of total GLP-1 in systemic
blood plasma 5 min after gavage with PBS (B bolus) or D-glucose
(G bolus; 6 mg/g body wt). *P < 0.05, **P < 0.01, ***P < 0.001, Student
t tests.
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with loss-of-function mutations in SGLT1 (SLC5A1) (18,19).
GGM is characterized by severe diarrhea and dehydration
as a result of osmotic loss by retention of nonabsorbed
D-glucose, D-galactose, and sodium in the small intestinal
lumen. In contrast with humans, where severe diarrhea
and dehydration are observed in suckling neonates, suck-
ling Sglt12/2 mice showed no obvious symptoms. This
species difference may be explained by the three to four
times higher concentrations of lactose in human milk
compared with murine milk (36,37). In the small intestine
lactose is degraded by lactase-isomaltase and provides the
only relevant source of D-glucose and D-galactose in suck-
ling neonates.
Confirming previous results (15,16) we showed that SGLT1
is expressed in the luminal membrane of enteroendocrine
cells staining positive for the incretin hormones, GLP-1
and GIP. Active forms of GLP-1 and GIP are detectable in
the systemic blood of human subjects after glucose in-
gestion (38,39), but are rapidly inactivated in the circulation
by DPP-IV (10). Both GIP and GLP-1 trigger glucose-
dependent insulin secretion, and although the effective-
ness of GIP is impaired in people with type 2 diabetes (40),
the preserved insulinotropic effect of GLP-1 (40) has led to
the successful development of GLP-1 mimetics and DPP-IV
inhibitors as new classes of antidiabetic agent (41). Earlier
in vitro studies have demonstrated that SGLT1-mediated
monosaccharide transport triggers incretin secretion via
the electrogenic coupled influx of Na+, which results in
membrane depolarization, electrical activity, voltage-gated
Ca2+ entry, and exocytosis (16,42), although the contribu-
tion of this pathway to glucose-mediated secretion in vivo
has remained controversial. Using the SGLT12/2 mice we
now demonstrate the pivotal role of SGLT1 for both GLP-1
and GIP secretory responses triggered by oral glucose in
vivo. This is consistent with the reported phlorizin sensi-
tivity of glucose-induced incretin increases in the portal
vein (13) showing the involvement of a phlorizin-sensitive
SGLT-type transporter or channel (3,30,43), as well as with
the finding that incretin secretion is triggered in vivo by
substrates of SGLT1 (44), but not by other sweet tasting
compounds (14). The results suggest that secretion of
these hormones would be initiated after food ingestion by
the early arrival of even small glucose loads in the small
intestine, consistent with previous reports that GLP-1 re-
lease is initiated in humans when glucose infusion rates
exceed the absorption capacity of the duodenum (45).
Whereas glucose is nearly completely reabsorbed by the
kidneys in wild-type mice, Sglt12/2 mice lose ;3% of the
filtered glucose in the urine, leading to a urinary D-glucose
concentration of ;20 mmol/L. Notably Sglt2 null mice lose
only ;60% of the filtered glucose in the urine although the
expression of SGLT1 was downregulated by 50% (20). This
suggests that wild-type mice do not use the maximal trans-
port capacity of SGLT1 at normoglycemic conditions. This is
different when the glucose load to the SGLT1-expressing
FIG. 6. Effects of SGLT1 removal on renal glucose excretion. A: D-glucose
concentrations measured in spontaneous urine collections and sub-
sequently obtained blood collections from tail vein of awake male mice
(for experimental details [29]). B: Absolute renal excretion and frac-
tional reabsorption of glucose in male Sglt12/2 versus Sglt1+/+ mice
as function of the amount of filtered glucose. GFR was measured in
awake mice using the plasma kinetics of FITC-inulin after a single
dose intravenous injection (26). Mean values 6 SE are shown. bw,
Body weight.
FIG. 7. Micropuncture studies in male wild-type and Sglt12/2 mice. Mice were anesthetized with thiobutabarbital (100 mg/kg i.p.) plus ketamine
(100 mg/kg i.m.) and prepared for renal micropuncture as described (20,27). A catheter was placed in the femoral artery for continuous blood
pressure recording, and a bladder catheter was applied for urine collections. For assessment of GFR, [3H]inulin was added to the infusion to deliver
20 mCi/h and urine was quantitatively collected. To determine proximal glucose reabsorption, quantitative free-flow fluid collections were made
from the last surface loop of proximal convoluted tubules and tubular fluid volume was determined from transfer to a constant bore capillary.
Concentrations of glucose in plasma, urine, and tubular fluid were determined as described (27). A: GFRs of single nephrons (SNGFR). B: Fil-
tration of D-glucose by single nephrons. C: D-glucose concentrations in the last surface loops of proximal tubules. D: Amount of D-glucose delivered
to the last surface loops of proximal tubules. E: Fractional reabsorption of D-glucose up to the last proximal tubular surface loops. Nephrons
(2–25) in five to six mice/genotype were investigated. Mean values 6 SE are shown. ***P < 0.001, Student t tests.
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S2 and S3 segments is increased. In diabetic patients in
which early proximal tubule glucose transport capacity is
overwhelmed by high D-glucose concentrations, and even
more in diabetic patients treated with an SGLT2 specific in-
hibitor, SGLT1 may operate at full transport capacity (17).
The Sglt1 null mice provide a valuable tool for future
studies of SGLT1 functions under pathological conditions
as well as the therapeutic potential of SGLT1 inhibition.
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